Pozelimab

• UNSPSC Description:

  Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases[1].

• Target Antigen:

  Complement System

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/pozelimab.html

• Purity:

  99.45

• Solubility:

  10 mM in DMSO

• Smiles:

  [Pozelimab]

• References & Citations:

  [1]Latuszek A, et al. Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020 May 8;15(5):e0231892.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Clinical Information:

  Launched

• CAS Number:

  2096328-94-6